Abstract 1604P
Background
Analysis of the most common prevalent symptoms among patients with advanced cancer diagnosis is needed in order to reach the most appropriate interventions leading to improved quality of life of these patients. The aim of this study is to report on the overall symptom prevalence among patients with advanced cancer diagnosis under palliative care and to analyze the difference of symptom prevalence between elderly (≥ 65 years) and adult (<65 years) patients.
Methods
A retrospective cohort study of 400 patients with advanced cancer who were admitted under palliative care between 1st January 2017 to December 31st, 2021. Data were retrieved from electronic medical records.
Results
Anorexia (91%), fatigue (98%), drowsiness (84%) and pain (83%) were the highest 4 prevalent symptoms for the whole group, followed by depression (76%) and anxiety (72%). Adult patients had significant higher pain (80% versus 76%), depression (83% versus 68%) and anxiety (77% versus 65%), compared to elderly (≥ 65 years) patients. On multivariate analysis, pain only was significantly higher in adult patients (p=0.021). The reported percentage of symptom prevalence for the whole group is higher than that in the literature, indicating late referral to palliative care.
Conclusions
There is a high percentage of symptom prevalence among our patients and a short median overall survival that indicates late referral to palliative care. Adult patients had significantly higher pain, depression, and anxiety compared to elderly patients. An earlier integration of palliative care is recommended in the overall management of our patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Medical Research Center.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1878P - Prevalence of burnout in GU oncologists in central Asia: BUCARE survey
Presenter: Oxana Shatkovskaya
Session: Poster session 05
1879P - Investigating the effect of family support on the mental health of patients with breast cancer
Presenter: Maryam Garousi
Session: Poster session 05
1880P - Cancer care: Psychoeducational intervention for first-year residents of a general hospital in northeastern Mexico
Presenter: Celia Beatriz Gonzalez-Alcorta
Session: Poster session 05
1991P - Safety and effectiveness of surgery or radiotherapy after PD-L1 Inhibitor (TQB-2450) and chemotherapy induction therapy in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Fenghuan Sun
Session: Poster session 05
1992P - A phase II safety and efficacy study of PM8002 (anti-PD-L1 x VEGF-A bispecific) combined with paclitaxel as a second-line therapy for small cell lung cancer (SCLC)
Presenter: Ying Cheng
Session: Poster session 05
1993P - Phase IIIb study of durvalumab plus platinum–etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Safety results
Presenter: Maria Dolores Isla Casado
Session: Poster session 05
1994P - Carboplatin, etoposide, bevacizumab, and atezolizumab in patients with extensive-stage SCLC – GOIRC-01-2019 CeLEBrATE ML41241 trial
Presenter: Karim Rihawi
Session: Poster session 05
1995P - Long-term benefit of atezolizumab plus chemotherapy in extensive stage small cell lung cancer (ES-SCLC): Exploratory analysis from the IMfirst study
Presenter: Maria Rosario Garcia Campelo
Session: Poster session 05
1996P - The impact of an etoposide shortage on patients with extensive-stage small cell lung cancer (ES-SCLC): Results of a natural experiment
Presenter: Claire Browne
Session: Poster session 05
1997P - A study of sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-disease small cell lung cancer
Presenter: Zhe-Hai Wang
Session: Poster session 05